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Clinics and pathology 
Disease 
Diffuse large cell lymphoma (DLCL) includes 
centroblastic lymphoma, B-cell immunoblastic 
lymphoma and B-cell large cell anaplastic lymphoma 
in the Kiel classification; this neoplasia may present as 
a de novo condition or it may derive from the 
transformation of follicle centre cell lymphoma or, less 
frequently, of marginal zone lymphoma. 
Phenotype/cell stem origin 
The tumor cells are pan-B+ and CD45+; CD5 and 
CD10 are positive in a minority of cases; positivity for 
surface Ig is found in the majority of cases, a minority 
of which also show intracytoplasmic Ig; some cases of 
the anaplastic subtype may be CD30+; usually, BCL6 
is positive in cases with predominant centroblastic 
morphology, whereas syndecan-1 (CD138) tests 
positive in the immunoblastic variant; the putative 
normal cellular counterparts are cells of follicle / post 
follicle centre origin that have encountered the antigen 
and harbour somatic hypermutations of the Ig-gene 
variable region. 
Pathology 
The cells are large, with vesicular nuclei at least twice 
the size of the nucleus of a small lymphocyte; there is a 
mixture of cells resembling centroblasts and 
immunoblasts; in rarer cases the cells are 
morphologically indistinguishable from those seen in 
anaplastic lymphoma of T- or null cell type. 
Genetics 
Note 
The large majority of cases show clonal cytogenetic 
lesions; some of these changes are associated with a 
known primary genetic defect responsible for 
lymphomagenesis, whereas a plethora of additional 
changes may be involved in tumor progression.  
Most studies failed to establish the prognostic 
predictivity for any primary chromosome defect, 
whereas there is evidence that several secondary 




t(14;18)(q32;q21) / BCL2-rearrangement: this 
molecular cytogenetic defect is found in approximately 
15-25% of the cases, many of which are thought to 
derive from the transformation of an antecedent follicle 
centre cell lymphoma; in virtually all cases additional 
cytogenetic defects are present, including 17p13/p53 
lesions; this balanced translocation can be 
demonstrated by conventional cytogenetics, by FISH 
and by molecular genetic methods, including southern 
blotting and PCR; the latter method is useful for the 
monitoring of minimal residual disease. 
t(3;V)(q27;V) / BCL6-rearrangement: chromosome 
translocations involving the 3q27 band with a number 
of partner chromosomes (14q32, 2p11, 22q11, 4p11, 
6p21, 11q23 ) are found in 5-10% of the cases by 
cytogenetic analysis, but the incidence of BCL6 
rearrangement may reach 20-30% of the cases when 
investigated by southern blotting; there is not an 
absolute correlation between rearrangement of the 3q27 
band and BCL6 involovement; cryptic BCL6 
rearrangements were demonstrated by FISH, consisting 
of an insertion of IgH sequences within the regulatory 
portion of the BCL6 gene. 
t(8;14)(q24;q32) / MYC rearrangements: this 
aberration is found by cytogenetic or molecular genetic 
methods in 7-10% of the cases; probes for FISH 
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detection of myc rearrangements were also tested 
succesfully; an association with the centroblastic 
variant of DLCL was proposed. 
Additional anomalies 
Secondary anomalies: 
Trisomies of chromosomes 3, 5, 7, 11, 12, 18 and X are 
usually encoutered in >10% of the cases. 
The most frequent monosomies include -13, -14, -15. 
Gains of 1q and 6p were reported in more than 10% of 
the cases. 
Frequently occurring deletions involve 1p, 6q, 7q32-
ter, 8p, 9p, 11q, 17p. 
The most frequent breakpoints are clustered in the 
following regions: 1cen-p13; 1p34-36; 3q21-22; 3q27-
29; 6q12-16; 6q21-25; 7q32, 9cen-p21; 17cen-p12. 
There are reports suggesting that an inferior prognosis 
may be associated with 1q21-23 breaks, with 1q23-32 
duplications, with 6q21-25 breaks and with 11q22-23 
deletion; complex karyotype may have an adverse 
impact on prognosis. 
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